Guggenheim Issues Positive Forecast for Insmed (NASDAQ:INSM) Stock Price

Key Points

• Guggenheim analysts raised their price target for Insmed stock from $125.00 to $172.00, indicating a potential upside of 17.94% from its previous close.
• The stock has received numerous "buy" ratings, with a consensus price target averaging around $139.86 from sixteen investment analysts.
• Despite a revenue increase of 18.9% year-over-year, Insmed reported a quarterly loss of ($1.70) EPS, missing the consensus estimate by $0.40.

Insmed (NASDAQ:INSM - Free Report) had its price objective boosted by Guggenheim from $125.00 to $172.00 in a research note released on Monday, MarketBeat.com reports. Guggenheim currently has a buy rating on the biopharmaceutical company's stock.

A number of other research firms have also commented on INSM. Bank of America raised their price objective on shares of Insmed from $94.00 to $109.00 and gave the stock a "buy" rating in a research note on Wednesday, June 11th. Mizuho increased their target price on Insmed from $130.00 to $165.00 and gave the company an "outperform" rating in a report on Wednesday, August 13th. The Goldman Sachs Group raised their target price on Insmed from $114.00 to $142.00 and gave the stock a "buy" rating in a research report on Wednesday, August 13th. HC Wainwright lifted their price target on Insmed from $90.00 to $120.00 and gave the company a "buy" rating in a report on Wednesday, June 11th. Finally, Jefferies Financial Group increased their price objective on Insmed from $129.00 to $148.00 and gave the stock a "buy" rating in a research note on Wednesday, August 13th. Sixteen investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $139.86.

Insmed Trading Down 0.9%

NASDAQ INSM traded down $1.27 on Monday, hitting $145.93. 1,515,925 shares of the company were exchanged, compared to its average volume of 2,503,490. The company has a debt-to-equity ratio of 0.45, a current ratio of 6.68 and a quick ratio of 6.33. Insmed has a twelve month low of $60.40 and a twelve month high of $149.08. The firm has a market capitalization of $30.85 billion, a P/E ratio of -25.56 and a beta of 0.97. The company's 50 day moving average price is $117.50 and its 200-day moving average price is $90.98.

Insmed (NASDAQ:INSM - Get Free Report) last announced its earnings results on Thursday, August 7th. The biopharmaceutical company reported ($1.70) EPS for the quarter, missing the consensus estimate of ($1.30) by ($0.40). The firm had revenue of $107.42 million during the quarter, compared to analyst estimates of $104.06 million. Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%.The business's quarterly revenue was up 18.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($1.94) earnings per share. Insmed has set its FY 2025 guidance at EPS. Analysts predict that Insmed will post -4.56 earnings per share for the current fiscal year.

Insider Transactions at Insmed

In other Insmed news, COO Roger Adsett sold 25,000 shares of the company's stock in a transaction dated Tuesday, August 19th. The stock was sold at an average price of $127.58, for a total value of $3,189,500.00. Following the transaction, the chief operating officer directly owned 105,637 shares of the company's stock, valued at $13,477,168.46. This represents a 19.14% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Michael Alexander Smith sold 24,272 shares of the firm's stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $143.89, for a total value of $3,492,498.08. Following the sale, the insider directly owned 54,902 shares of the company's stock, valued at $7,899,848.78. This trade represents a 30.66% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 378,382 shares of company stock valued at $40,169,038. Corporate insiders own 3.00% of the company's stock.

Institutional Trading of Insmed

A number of institutional investors have recently added to or reduced their stakes in INSM. Norges Bank bought a new stake in Insmed in the second quarter worth approximately $194,728,000. Adage Capital Partners GP L.L.C. lifted its stake in shares of Insmed by 109.2% in the 1st quarter. Adage Capital Partners GP L.L.C. now owns 3,446,944 shares of the biopharmaceutical company's stock valued at $262,967,000 after purchasing an additional 1,799,382 shares during the last quarter. Orbis Allan Gray Ltd acquired a new stake in shares of Insmed in the 2nd quarter valued at $153,389,000. Nuveen LLC acquired a new position in Insmed during the first quarter worth $88,351,000. Finally, Qube Research & Technologies Ltd bought a new position in Insmed during the second quarter valued at about $108,898,000.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.